Claims
- 1. An aromatic heterocyclic compound having the formula ##STR20## wherein R.sub.1 represents (i) --CH.sub.3, (ii) --CH.sub.2 OH or (iii) ##STR21## R.sub.3 represents hydrogen, --OR.sub.4 wherein R.sub.4 represents hydrogen, alkyl having 1-20 carbon atoms, mono- or polyhydroxyalkyl, or R.sub.3 represents ##STR22## wherein r'and r" represent hydrogen, lower alkyl or r' and r" together with the nitrogen atom to which they are attached form a pyrrolidino group,
- R.sub.2 represents hydrogen or --CH.sub.3,
- Ar represents an aromatic radical having one of the following formulas ##STR23## wherein Z is O or S, ##STR24## wherein R.sub.5 represents lower alkyl, and ##STR25## where R.sub.6 represents hydrogen or alkyl having 1-10 carbon atoms and R.sub.7 represents branched alkyl having 4-12 carbon atoms or cycloalkyl,
- Y represents a nitrogen atom, and
- X represents --N--R.sub.8 wherein R.sub.8 represents hydrogen, lower alkyl or lower alkoxycarbonyl.
- 2. The compound of claim 1 having the formula ##STR26## wherein R.sub.1 represents --CH.sub.2 OH or ##STR27## R.sub.3 represents --OR.sub.4 or ##STR28## R.sub.4 represents hydrogen, or --CH.sub.3 or --CH.sub.2 CH.sub.2 OH, r' and r" each independently represent hydrogen or lower alkyl,
- Y represents a nitrogen atom, and
- X represents --N--R.sub.8 wherein R.sub.8 represents hydrogen, --CH.sub.3 or --CO.sub.2 t-butyl.
- 3. The compound of claim 1 having the formula ##STR29## wherein R.sub.4 represents hydrogen or --CH.sub.3,
- Y represents a nitrogen atom, and
- X represents --N--R.sub.8 wherein R.sub.8 represents hydrogen or --CO.sub.2 t-butyl.
- 4. The compound of claim 1 having the formula ##STR30## wherein R.sub.4 represents hydrogen or --CH.sub.3,
- R.sub.6 represents --CH.sub.3 or --C.sub.10 H.sub.21,
- R.sub.7 represents t-bytyl, 1,1-dimethyldecyl or adamantyl,
- Y represents a nitrogen atom, and
- X represents --N-R.sub.8 wherein R.sub.8 is hydrogen.
- 5. The compound of claim 1 selected from the group consisting of
- methyl 2-(p-t-butylphenyl)-5-benzimidazole carboxylate,
- 2-(p-t-butylphenyl)-5-benzimidazole carboxylic acid,
- methyl 2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-5-benzimidazole carboxylate,
- 2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-5-benzimidazole carboxylic acid,
- methyl 2-[3-(1-adamantyl)-4-methoxyphenyl]-5-benzimidazole carboxylate,
- 2-[3-(1-adamantyl)-4-methoxyphenyl]-5-benzimidazole carboxylic acid,
- methyl 2-[3-(1-adamantyl)-4-hydroxyphenyl]-5-benzimidazole carboxylate and
- methyl 2-(4,4-dimethyl-2,3,-dihydro-1-benzopyran-6-yl)-5-benzimidazole carboxylate.
- 6. The compound of claim 1 which is 2-[3-(1-adamantyl)-4methoxyphenyl]-5-benzimidazole carboxylic acid.
- 7. The compound of claim 1 wherein said lower alkyl has 1-6 carbon atoms.
- 8. The compound of claim 20 wherein said lower alkyl is methyl, ethyl, isopropyl, butyl or t-bytyl.
- 9. The compound of claim 1 wherein said monohydroxyalkyl has 2-3 carbon atoms and is selected from the group consisting of 2-hydroxyethyl and 2-hydroxypropyl and wherein said polyhydroxy alkyl is derived from glycerol, pentaerythritol or mannitol.
- 10. The compound of claim 1 wherein said lower alkoxy carbonyl is methoxy carbonyl, ethoxy carbonyl, isopropoxy carbonyl or t-butoxy carbonyl.
- 11. The compound of claim 1 wherein said cycloalkyl is cyclohexyl, 1-methylcyclohexyl or adamantyl.
- 12. A composition for the treatment of dermatologic ailments linked to a keratinization disorder comprising the compound of claim 1.
- 13. A composition of claim 12 administered at a daily dosage of about 1 .mu.g to 2 mg/kg of body weight.
- 14. A pharmaceutical composition for enteral, parenteral, topical or ocular administration for the treatment of dermatologic ailments linked to a keratinization disorder comprising in a pharmaceutically acceptable vehicle an amount of the compound of claim 1 effective to treat said dermatologic ailments.
- 15. The pharmaceutical composition of claim 14 wherein said compound is present in an amount ranging from 0.0005 to 5 percent by weight based on the total weight of said composition.
Priority Claims (1)
Number |
Date |
Country |
Kind |
85544 |
Sep 1984 |
LUX |
|
Parent Case Info
This is continuation of application Ser. No. 839,269, now U.S. Pat. No. 4,740,519, filed Mar. 13, 1986 which is a continuation-in-part of Ser. No. 777,728, filed Sept. 19,1985, now abandoned.
Non-Patent Literature Citations (1)
Entry |
Salem et al. Chem Abstracts, vol. 105, No. 12; 191007b (1986). |
Divisions (1)
|
Number |
Date |
Country |
Parent |
839269 |
Mar 1986 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
777728 |
Sep 1985 |
|